{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Major+Adverse+Cardiac+Event+%28MACE%29",
    "query": {
      "condition": "Major Adverse Cardiac Event (MACE)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Major+Adverse+Cardiac+Event+%28MACE%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T13:29:31.388Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03793582",
      "title": "Impact of OSA on Outcomes in Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "OSA",
        "ACS - Acute Coronary Syndrome",
        "Major Adverse Cardiac Events"
      ],
      "interventions": [
        {
          "name": "ApneaLink Type III portable sleep study",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "MetroHealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2017-08-29",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-12-14",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793582"
    },
    {
      "nct_id": "NCT01103440",
      "title": "Aspirin Resistance and Percutaneous Coronary Intervention (PCI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Angina"
      ],
      "interventions": [
        {
          "name": "Intravenous Glycoprotein inhibitor + ASA, Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Antiplatelet Therapy (ASA, Clopidogrel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2007-04",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-14",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01103440"
    },
    {
      "nct_id": "NCT07162376",
      "title": "How Clinical and Personal Information Shape Physicians' Risk Judgments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Adverse Cardiac Event (MACE)"
      ],
      "interventions": [
        {
          "name": "Personal Information Disclosure",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Maryland, College Park",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-09-16",
      "completion_date": "2025-09-26",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 1,
      "location_summary": "College Park, Maryland",
      "locations": [
        {
          "city": "College Park",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07162376"
    },
    {
      "nct_id": "NCT06383390",
      "title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerotic Cardiovascular Disease (ASCVD)",
        "Chronic Kidney Disease (CKD)"
      ],
      "interventions": [
        {
          "name": "Retatrutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2024-04-30",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 205,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 158 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06383390"
    },
    {
      "nct_id": "NCT06951867",
      "title": "Tezspire Cardiac Events PASS",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Events",
        "MACE"
      ],
      "interventions": [
        {
          "name": "Tezepelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 16640,
      "start_date": "2025-09-15",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06951867"
    },
    {
      "nct_id": "NCT01000727",
      "title": "The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Darapladib 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13026,
      "start_date": "2009-12-01",
      "completion_date": "2014-04-24",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 290,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01000727"
    },
    {
      "nct_id": "NCT06257628",
      "title": "MACE CDS Software Master Enrollment Protocol",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiac Events"
      ],
      "interventions": [
        {
          "name": "Index Event",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Beckman Coulter, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "23 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-09-14",
      "completion_date": "2025-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Detroit, Michigan • Kettering, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kettering",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06257628"
    },
    {
      "nct_id": "NCT01601704",
      "title": "Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "NB32",
          "type": "DRUG"
        },
        {
          "name": "PBO",
          "type": "DRUG"
        },
        {
          "name": "Weight Management Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 8910,
      "start_date": "2012-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 224,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01601704"
    },
    {
      "nct_id": "NCT00868855",
      "title": "Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Bradykinin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2003-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868855"
    },
    {
      "nct_id": "NCT00799903",
      "title": "The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Darapladib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15828,
      "start_date": "2008-12-01",
      "completion_date": "2013-10-17",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-07-23T13:29:31.388Z",
      "location_count": 155,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799903"
    }
  ]
}